Trial Profile

An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions; Registrational
Acronyms ALITHIOS
Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals

Most Recent Events

25 Mar 2025 According to a Novartis Media Release, data from the study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9, 2025.
20 Mar 2025 Status changed from recruiting to active, no longer recruiting.
20 Nov 2024 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com